Document:

EX-10.32

 Exhibit 10.32 

FIRST AMENDMENT TO SUPPLY AGREEMENT 

This first amendment (“First Amendment”) to the Supply Agreement by and between MannKind Corporation (“MannKind”) and
Amphastar France Pharmaceuticals S.A.S. (“AFP”), dated July 31, 2014 (the “Agreement”), is hereby made as of the 31st day of October, 2014, by and between MannKind on the one hand, and on the other hand, AFP and
Amphastar Pharmaceuticals, Inc., a Delaware Corporation, having its principal office and place of business at 11570 6th Street, Rancho Cucamonga, CA 91730 (“Amphastar”). 

RECITALS: 
 WHEREAS,
MannKind and AFP entered into the Agreement pursuant to which AFP is to manufacture and supply the Product to MannKind, and MannKind is to purchase certain minimum quantities of the Product; 

WHEREAS MannKind and AFP, together with Amphastar, the parent company of AFP, have determined it to be mutually beneficial to amend the
Agreement as set forth herein. 
 NOW, THEREFORE, for good and valuable consideration, MannKind and AFP, together with Amphastar, hereby
agree to amend the Agreement as follows: 
 1. Definitions. Unless otherwise defined herein, each of the capitalized terms
used in this First Amendment shall have the definition and meaning ascribed to it in the Agreement. 
 2. Amendments to the
Agreement. 
 2.1 All references to “AFP” in the Agreement are replaced with “Amphastar.” For avoidance of
doubt, Amphastar shall replace AFP as a party to the Agreement, and AFP shall no longer be a party to the Agreement. 
 2.2 For
avoidance of doubt, Amphastar shall assume all of AFP’s rights and obligations under the Agreement. 
 2.3 With respect to
Amphastar’s obligations under the Agreement, Amphastar either shall perform, or shall cause AFP to perform, all such obligations under the Agreement. 

2.4 Section 4.4 of the Agreement is amended and replaced in its entirety with the following: 

“4.4 Audits. Upon MannKind’s written request to Amphastar, which shall be not less than thirty
(30) days in advance, MannKind, or a mutually agreed upon independent third party representative on behalf of MannKind’s licensee(s) identified in such a written request (“Licensee’s Representative”), shall have the right to
visit Amphastar’s facility located at Usine Saint Charles, 60590 Eragny-sur-Epte, France, during normal business hours to review and inspect Amphastar’s manufacturing operations and quality systems related to the Product and to discuss any
related issues with Amphastar’s manufacturing and management personnel. Such audits of Amphastar shall not exceed one (1) time per calendar year for MannKind and shall not exceed one (1) time per calendar year for MannKind’s
Licensee’s Representative. For the avoidance of doubt, only two (2) audits in total are allowed per calendar year. MannKind, or the Licensee’s Representative will be entitled to perform additional audits, upon shorter
notice, if Non-conforming Products are produced by Amphastar or complaints or other inquiries by regulatory authorities relating to the Products produced hereunder are received by either Party, or for any additional reasons where good cause is
articulated in writing by MannKind. 

  
 - 1 - 

 2.5 The following sentence in section 6.1 of the Agreement: 

“All amounts due under this § 6.1 shall be due and payable by MannKind to AFP in EUR in accordance with § 6.2.” 

is amended and replaced in its entirety with the following: 

“All amounts due under this § 6.1 shall be due and payable by MannKind to Amphastar in U.S. dollars, and the conversion of the
Purchase Price from euros (EUR) to U.S. dollars shall be made using the exchange rate at the close (Eastern time) of the last business day immediately prior to the shipment date, as reported by the Bloomberg Currency Spot Exchange Rate
(http://www.bloomberg.com/quote/EURUSD:CUR), and otherwise in accordance with § 6.2.” 
 2.6 Section 11.1 of the
Agreement is amended by adding the following sentence at the end of section 11.1: “MannKind’s obligations under this section 11.1 shall apply to Confidential Information MannKind receives from Amphastar or Amphastar’s
Affiliates.” 
 3. Final Agreement. 

From and after the execution of this First Amendment, all references in the Agreement (or in the First Amendment) to “this
Agreement,” “hereof,” “herein,” “hereto,” and similar words or phrases shall mean and refer to the Agreement as amended by this First Amendment. The Agreement as amended by this First Amendment constitutes the
entire agreement by and between the Parties as to the subject matter hereof. Except as expressly modified by this First Amendment, all other terms and conditions of the Agreement shall remain in full force and effect. 

  
 - 2 - 

 IN WITNESS WHEREOF, each of MannKind, AFP, and Amphastar has caused this First Amendment to be
executed by their duly authorized officers. 
  

			
	MannKind Corporation
		
	By:	 	 /s/ Kathleen M. Farley

	Name:	 	Kathleen M. Farley
	Title:	 	V.P. Strategic Operations
	
	Amphastar France Pharmaceuticals S.A.S.
		
	By:	 	 /s/ Franck Vitali

	Name:	 	Franck Vitali
	Title:	 	Plant Manager
	
	Amphastar Pharmaceuticals, Inc.
		
	By:	 	 /s/ Jason Shandell

	Name:	 	Jason Shandell
	Title:	 	President

  
 - 3 -EX-10.33

 Exhibit 10.33 

***Text Omitted and Filed Separately 

with the Securities and Exchange Commission. 

Confidential Treatment Requested 

Under 17 C.F.R. Sections 200.80(b)(4) 

and 240.24b-2. 
 SECOND
AMENDMENT TO SUPPLY AGREEMENT 
 This second amendment (“Second Amendment”) to the Supply Agreement by and between MannKind
Corporation (“MannKind”) and Amphastar Pharmaceuticals, Inc. (“Amphastar”), originally dated July 31, 2014 and as previously amended on October 31, 2014 (collectively, the “Agreement”), is hereby made as of
the 9th day of November, 2016, by and between MannKind on the one hand, and on the other hand, Amphastar. 

RECITALS: 
 WHEREAS,
MannKind and Amphastar entered into the Agreement pursuant to which Amphastar is to manufacture and supply the Product to MannKind, and MannKind is to purchase certain minimum quantities of the Product; 

WHEREAS, MannKind and Amphastar are concurrently entering into a first amendment to the Insulin Purchase Option Agreement originally dated
January 1, 2015 (the “Option Amendment”) and 
 WHEREAS MannKind and Amphastar have determined it to be mutually beneficial
to amend the Agreement as set forth herein. 
 NOW, THEREFORE, for good and valuable consideration, MannKind and Amphastar, hereby agree to
amend the Agreement as follows: 
 1. Definitions. Unless otherwise defined herein, each of the capitalized terms used in this Second
Amendment shall have the definition and meaning ascribed to it in the Agreement. 
 2. Amendments to the Agreement. 

2.1 The following sentence in Section 5.1 of the Agreement: 

“Upon delivery to MannKind, AFP shall ensure Product will have a remaining expiry date of not less than four (4) years.” 

Is amended and replaced in its entirety with the following: 

“In calendar year 2017 and 2018, upon delivery to MannKind, Amphastar shall ensure that Product will have a remaining expiry date of not
less than two (2) years. In calendar year 2019 and the remainder of the term of the Agreement, Amphastar shall ensure Product will have a remaining expiry date of not less than three (3) years.” 

2.2 The following sentence in Section 6.1 of the Agreement: 

“Purchase Commitment and Purchase Price. MannKind shall purchase from AFP the minimum quantities of Product (the
“Purchase Commitment Quantities”) at the purchase price per gram (the “Purchase Price”) in each calendar year as provided in the table set forth below. In the event that MannKind fails to meet the
Purchase Commitment Quantities in any given calendar year, MannKind shall pay AFP for the difference in the amount of the Purchase Commitment Quantities and the actual amount purchased for the corresponding calendar year (such difference, the
“Purchase Commitment Difference”). AFP shall issue an invoice and MannKind shall pay the Purchase Commitment Difference no later than thirty (30) days after the close of the corresponding calendar year.” 

is amended and replaced in its entirety with the following: 

 Purchase Commitment and Purchase Price. MannKind shall purchase from Amphastar the minimum
quantities of Product (the “Purchase Commitment Quantities”) at the purchase price per gram (the “Purchase Price”) in each calendar year as provided in the table set forth below. This annual Purchase
Commitment Quantities will be divided into four (4) equal quarterly commitments (the “Quarterly Commitment”). In the event that MannKind fails to meet the Quarterly Commitment in any given calendar quarter, MannKind
shall pay Amphastar for the difference in the amount of the Quarterly Commitment and the actual amount purchased for the corresponding calendar quarter (such difference, the “Payment Commitment Difference”). Amphastar shall
issue an invoice and MannKind shall pay the Payment Commitment Difference no later than thirty (30) days after the close of the corresponding calendar quarter. Notwithstanding the foregoing, the parties hereby agree that the Purchase Commitment
Quantities for 2017 shall not be divided into four (4) equal quarterly payments but rather MannKind shall take receipt of the entire [*...***...] Kgs of Product in the
fourth (4th) quarter of 2017 but no later than November 15, 2017. 

2.3 The table in Section 6.1 of the Agreement is amended and replaced in its entirety with the following: 

 

							
	 Calendar
Year
	  	 Purchase Commitment
Quantities (kg)
	  	 Purchase Price
(per gram)
	  	 Delivery and Payment

				
	2014	  	[***]	  	EUR [***]	  	
				
	2015	  	[***]	  	EUR [***]	  	
				
	2016	  	[***]	  	EUR [***]	  	
				
	2017	  	[***]	  	EUR [***]	  	100% of the Purchase Commitment Quantities Payment shall be paid no later than November 5, 2017
				
	2018	  	[***]	  	EUR [***]	  	25% of the Purchase Commitment Quantities shall be paid on a Quarterly basis
				
	2019	  	[***]	  	EUR [***]	  	25% of the Purchase Commitment Quantities shall be paid on a Quarterly basis
				
	2020	  	[***]	  	EUR [***]	  	25% of the Purchase Commitment Quantities shall be paid on a Quarterly basis
				
	2021	  	[***]	  	EUR [***]	  	25% of the Purchase Commitment Quantities shall be paid on a Quarterly basis
				
	2022	  	[***]	  	EUR [***]	  	25% of the Purchase Commitment Quantities shall be paid on a Quarterly basis
				
	2023	  	[***]	  	EUR [***]	  	25% of the Purchase Commitment Quantities shall be paid on a Quarterly basis

  

	***	Confidential Treatment Requested 

  
 - 2 - 

 2.4 Section 6.2 of the Agreement shall be amended and replaced in its
entirety with the following: 
 6.2 Payment. In calendar year 2017 and 2018, MannKind shall pre-pay Amphastar for the Product at least
ten (10) days prior to the estimated delivery date. For the avoidance of doubt, Amphastar shall not ship the Product to MannKind until such payment is received. Beginning in 2019 and for the remainder of the term of the Agreement, MannKind
shall pay Amphastar for the Product within forty-five (45) days from shipment date of the Product. Amphastar shall submit an invoice electronically to MannKind, Attention: Account Payable, valenciaap@mannkindcorp.com. If any portion of
an invoice is disputed then MannKind shall pay the undisputed amount and the Parties shall use good faith efforts to reconcile the disputed amount as soon as practicable. 

2.5 A new Section 6.5 shall be added to the Agreement as follows: 

6.5 Right of First Refusal in China. In consideration of the amendments contained in this Second Amendment and in the Option Amendment,
MannKind hereby grants Amphastar the right of first refusal to participate in the development and commercialization of Afrezza in China through a collaborative arrangement. Specifically, Amphastar and MannKind agree that MannKind will not commence
the process of obtaining approval of Afrezza in China without first providing Amphastar with (i) at least ninety (90) days prior written notice of MannKind’s intention to commence the process of obtaining approval of Afrezza in China,
and (ii) if Amphastar confirms its interest in collaborating in the development or commercialization of Afrezza in China in writing within thirty (30) days of receipt of MannKind’s notice, then the Parties shall reserve sixty
(60) days to negotiate in good faith the terms of such a collaborative arrangement for Afrezza in China. In the event that the Parties are unable to agree on commercial terms for a collaborative agreement after the sixty (60) day
negotiation period, then MannKind shall have the right to negotiate a collaborative agreement with another party (“Competing Terms”). MannKind shall present the Competing Terms to Amphastar in writing, and within sixty (60) days of
receipt of the Competing Terms, Amphastar shall have the option to either (i) decline to match the Competing Terms, or (ii) agree to match the same Competing Terms and enter into a collaborative agreement with MannKind in China. 

2.6 Section 10.1 of the Agreement shall be extended until December 31, 2023. All other terms and conditions in
paragraph 10.1 shall remain in full force and effect. 
 3. Final Agreement. 

From and after the execution of this Second Amendment, all references in the Agreement (or in the Second Amendment) to “this
Agreement,” “hereof,” “herein,” “hereto,” and similar words or phrases shall mean and refer to the Agreement as amended by this Second Amendment. The Agreement as amended by this Second Amendment constitutes the
entire agreement by and between the Parties as to the subject matter hereof. Except as expressly modified by this Second Amendment, all other terms and conditions of the Agreement shall remain in full force and effect. 

  
 - 3 - 

 IN WITNESS WHEREOF, each of MannKind and Amphastar has caused this Second Amendment to be
executed by their duly authorized officers. 
  

			
	MannKind Corporation
		
	By:	 	 /s/ Matthew Pfeffer

	Name:	 	Matthew Pfeffer
	Title:	 	CEO
	
	Amphastar Pharmaceuticals, Inc.
		
	By:	 	 /s/ Jason Shandell

	Name:	 	Jason Shandell
	Title:	 	President

  
 - 4 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}]]